Another Multibagger from my desk in 2010

SBIL Details
Saamya Biotech (India) Limited engages in the manufacture and marketing of various chemicals, pharmaceuticals, drugs, and intermediates in India. It manufactures low volume and high value active bio-pharmaceutical ingredients, including daunomycin and hyaluronic acid–pharma grade and cosmetic grade. Its daunomycin is used for remission induction of acute lymphocytic leukaemia in combination with other drugs. The company’s hyaluronic acid acts as the natural moisturizing factor and used in cosmetics and as indictable in ophthalmic surgery and osteoarthritis treatments. Saamya Biotech (India) Limited was incorporated in 2002 and is based in Hyderabad, India

Saamya Biotech has entered into a joint venture agreement with Perak Bio Corporation Sdn. Bhd. (PBC) to setup a bio-pharmaceutical manufacturing unit in Perak state for Saamya Biotech (Malaysia) Sdn. Bhd, a subsidiary of the Indian company.

PBC is a company owned by state government of Perak in Malaysia. It has allotted 12.63 acres land to Saamya Biotech (Malaysia) Sdn. Bhd, for the said project towards the equity participation of Perak state government.

Saamya Biotech India is a Hyderabad-based company that manufactures and markets biopharmaceuticals and recombinant protein products of medical and industrial importance, and also to discover and develop emerging biotech products of far reaching significance.

Past Key developments for SAAMYA BIOTECH INDIA LTD (SBIL)
Saamya Biotech To Approve Fund Raising Through Postal Ballot
12/30/2009
Saamya Biotech (India) Limited informed the Bombay Stock Exchange that the member of the Company will consider to approve the following resolution by way of Postal Ballot: To create issue, offer and allot (including with provisions for reservation on firm and/or competitive basis, of such part of issue and for such categories of persons including employees of the Company as may be permitted), Equity Shares and/or Equity Shares through depository receipts including American Depository Receipts (ADR), Global Depository Receipts (GDR) and/or Convertible Bonds (CB), Convertible Debentures (CD), fully or partly, and/or other securities convertible into Equity Shares at the option of the Company and/or the holder(s) of such securities, and/or securities linked to Equity Shares and/or securities with or without detachable/non-detachable warrants and/or warrants with a right exercisable by the warrant-holder to subscribe for Equity Shares and/or any instruments or securities representing either Equity Shares, secured premium notes, and/ or any other financial instruments which would be converted into/ exchanged with Equity Shares at a later date (Securities) as the Board at its sole discretion or in consultation with underwriters, merchant bankers, financial advisors or legal advisors may at any time decide, by way of one or more public, follow-on, preferential issues or private offerings in domestic and/or one or more international market(s), with or without a green shoe option, or private placement or issued /allotted through Qualified Institutions Placement in accordance with the Guidelines for Qualified Institutions Placement prescribed under Chapter XIII-A of the SEBI (Disclosure and Investor Protection) Guidelines, 2000, read with SEBI (Issue Of Capital And Disclosure Requirements) Regulations, 2009 as amended, or by any one or more or a combination of the above model/methods or otherwise and at such time or times and in one or more tranches, whether rupee denominated or denominated in foreign currency, to any eligible Qualified Institutional Buyers including Foreign Institutional Investors, resident/ non-resident investors (whether institutions, incorporated bodies, mutual funds, individuals or otherwise), Venture Capital Funds (foreign or Indian), Indian and/or Multilateral Financial Institutions, Mutual Funds, Non-Resident Indians, stabilizing agents and/or any other categories of investors, whether they be holders of shares of the Company or not (collectively called the Investors) whether or not such Investors are members of the Company as may be deemed appropriate by the Board and permitted under applicable laws and regulations, resulting in the issue of an aggregate amount not exceeding $40 Millions or equivalent thereof and on such terms and conditions and timing of the issue(s)/offering(s) including the Investors to whom the Securities are to be issued, issue price, number of Securities to be issued, creation of mortgage/ charge in accordance with Section 293(1)[a) of the Companies Act, 1956 in respect of any Securities as may be required either on pari-passu basis or otherwise, the stock exchanges on which such Securities will be listed, finalization of allotment of the Securities on the basis of the subscriptions received, face value, rate of interest, redemption period, manner of redemption, amount of premium on redemption, the number of equity share to be allotted on redemption/conversion, the ratio, period of conversion, fixing of record date or book closure dates, and any other matter in connection with, or incidental to, the issue, in consultation with the merchant bankers or other advisors or otherwise, as the Board at its sole discretion may decide together with any amendments or modifications thereto, subject to necessary provisions & approvals.

Saamya Biotech Mulls Raising $40 Million
12/17/2009
Saamya Biotech (India) Limited informed the Bombay Stock Exchange that the company on its meeting on December 17, 2009 has decided to issue, offer and allot further shares in all or any one or in combination of Equity Shares, GDR, ADR, Convertible Bonds / Debentures and / or other securities to the extent of $40 millions subject to approval of the members of the Company, to issue equity shares / warrants on preferential basis and to conduct postal ballot to accord consent of the Members of the Company for the aforesaid business.

Saamya Biotech To Mull Funding Options
12/14/2009
Saamya Biotech (India) Ltd. will be meeting on December 17, 2009 to consider issue further shares under GDR mechanism/ Preferential Allotment / QIB, etc., subject to approval of the members of the Company.


Stock History:

Volume 26,345
Prev Close 10.04
Day's H/L (Rs) 10.49 - 9.54
52wk H/L (Rs) 14.10 - 3.57
Mkt Cap (Rs Cr) 24.23

Project Progress:
Kedah Govt. of Malaysia agreed to provide 10 acre land in the Biotechnology park. A joint venture agreement with the Kedah state Govt. has been entered by the main promoter and collaborator, M/s Saamya Biotech (India) limited, in respect of land and equity participation. Govt. incentives for tax exemptions, Research grants, personnel training grant and permission for expatriate posts have also been obtained. Funding approvals from Federal Govt. and financial institutions are awaited.
The company entered into Technology transfer agreement with Saamya Biotech (India) Ltd., the main promoter company.


The parent and main promoter company, Saamya Biotech (India) Ltd. has entered into marketing agreement with Arch Pharmalabs Ltd., Mumbai, India for 100% marketing of the products that are manufactured by Saamya Biotech (Malaysia) Sdn. Bhd.


Saamya Biotech (India) Ltd., the parent and main promoter company, has signed an agreement with M/s Shapoorji Pallonji & Co. Ltd., Mumbai, India for execution of the project (construction/ basic and detailed engineering etc) on turnkey basis.


NOC from Pollution Control Board for establishing the facility, being planned.


Necessary statutory permissions from Malaysian Govt. will be obtained.

Conclusion:

Saamya Biotech is looking very attractive at this level.Guys pls keep your eyes open for this stock.I am very confident and optimistic this is one the way to become a multibagger in comming days. If thing goes in proper direction then I want to see Saamya Biotech at Rs 50-60 level within a year.
Currently it is trading at Rs 10.00. Go for it guys and it will enrich your portfolio.It can gives you atleast 10-15 times return in 2-3 years.